Friday, February 05, 2021 8:20:36 AM
Recent SAVA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:29:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 01:10:10 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/04/2024 09:09:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 12:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 08:37:36 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/01/2024 08:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 11:36:59 AM
- Cassava Sciences Resolves SEC Investigation • GlobeNewswire Inc. • 09/26/2024 10:15:00 PM
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 09/24/2024 12:30:00 PM
- Cassava Sciences Names Rick Barry as Chief Executive Officer • GlobeNewswire Inc. • 09/09/2024 12:30:00 PM
- Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:31:00 PM
- Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson • GlobeNewswire Inc. • 08/05/2024 01:01:00 PM
- Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET • GlobeNewswire Inc. • 08/01/2024 12:30:00 PM
- Cassava Sciences Announces Expansion of Open-Label Extension Trials • GlobeNewswire Inc. • 07/30/2024 12:15:00 PM
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Cassava Sciences Issues Statement on Former Science Advisor • GlobeNewswire Inc. • 06/28/2024 07:58:09 PM
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam • GlobeNewswire Inc. • 05/10/2024 08:02:00 PM
- Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution • GlobeNewswire Inc. • 05/08/2024 03:00:00 PM
- Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ • GlobeNewswire Inc. • 05/01/2024 01:10:00 PM
- Redemption Date Announced for Warrants • GlobeNewswire Inc. • 04/15/2024 01:20:00 PM
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 03/25/2024 01:13:00 PM
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference • GlobeNewswire Inc. • 03/04/2024 02:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:01:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:22:12 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM